Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
| ▸ | CCR9 | P51686 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24268105 | 0.84 | KCNA5 (0.59) | KCNA5CCR9LMNAHTT | |
| SCHEMBL24268032 | 0.84 | POLB (0.43) | KCNA5CCR9MAPTMETAP2 | |
| SCHEMBL24268096 | 0.82 | KDM1A (0.42) | CCR9 | |
| SCHEMBL24268056 | 0.82 | KDM4E (0.39) | KCNA5CCR9 | |
| SCHEMBL24268127 | 0.80 | HSD17B2 (0.42) | CCR9 | |
| SCHEMBL23879649 | 0.78 | ALDH1A1 (0.44) | KCNA5 | |
| SCHEMBL23879617 | 0.77 | MRGPRX1 (0.40) | KCNA5CCR9 | |
| SCHEMBL23879614 | 0.76 | PTGDR2 (0.47) | KCNA5HTTMAPTKMT2A | |
| SCHEMBL24268122 | 0.76 | POLB (0.42) | LMNAMAPT | |
| SCHEMBL23879590 | 0.74 | ALDH1A1 (0.62) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | KCNA5 264/4885CCR9 4670/4885LMNA 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.